Selegiline as immunostimulant — a novel mechanism of action?

  • Th. Müller
  • W. Kuhn
  • R. Krüger
  • H. Przuntek
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)


In clinical studies the MAO-B inhibitor selegiline appears to slow the progression of neurological deficits in Parkinson’s disease (PD) and the cognitive decline in Alzheimer’s disease (AD). The mechanisms of action remain unclear. Several lines of evidence indicate an immune-mediated pathophysiology of PD and AD. According to animal trials, selegiline increases the survival rate of immune suppressed mice. Stimulation of the immune response to bacterial or viral infection or in chronic inflammatory processes is managed by an increased synthesis of the cytokines interleukin-lß (IL-1ß) and subsequent interleukin-6 (IL-6). Outcome of viral or bacterial infections in the brain highly correlates with levels of the cytotoxic cytokine tumor-necrosis-factor-alpha (TNF). The aim of our study was to characterize the influence of selegiline on the biosynthesis of IL-1ß, IL-6 and TNF in human peripheral blood mononuculear cells (PBMC) from healthy blood donors. After isolation and washing PBMC were cultured without and with selegiline in three different concentrations (0.01 μmol/l, 0.001 μmol/l, 0.0001 μmol/l) in a humidified atmosphere (7% CO2). Then cultures were centrifuged and supernatants were collected for IL-1ß, IL-6 and TNF ELISAassays. Treatment of cultured PBMC with various concentrations induced an increased synthesis of IL-lß (ANOVA F = 9.703, p = 0.0007), IL-6 (ANOVA F = 20.648, p = 0.0001) and a reduced production of TNF (ANOVA F = 3.770, p = 0.040). These results indicate, that the influence of selegiline on the cytokine biosynthesis may also contribute to its putative neuroprotective properties.


Healthy Blood Donor Human Peripheral Blood Leukocyte Septal Cholinergic Neuron Chronic Relapse Experimental Autoimmune Encephalomyelitis Organum Vasculosum Lamina Terminalis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bartfai T, Schultzberg M (1993) Cytokines in neuronal cell types. Neurochem Int 22: 435–444PubMedCrossRefGoogle Scholar
  2. Bauer J, Strauss S, Schreiter Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett 285: 111–114PubMedCrossRefGoogle Scholar
  3. Blum-Degen D, Müller Th, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1-beta and interleukin 6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20PubMedCrossRefGoogle Scholar
  4. Boka G, Anglade P, Wallach D, Javoy Agid F, Agid Y, Hirsch EC (1994) Immunocy-tochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 172: 151–154PubMedCrossRefGoogle Scholar
  5. Brosnan CF, Selmaj K, Raine CS (1988) Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuro-immunol 18: 87–94Google Scholar
  6. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E (1991) Cerebrospinal fluid interleukin-1ß (IL-1ß) in Alzheimer’s disease and neurological disorders. Meth Find Exp Clin Pharmacol 13: 455–458Google Scholar
  7. Calne DB (1995) Selegiline in Parkinson’s disease. BMJ 311: 1583–1584PubMedCrossRefGoogle Scholar
  8. Freisleben HJ, Lehr F, Fuchs J (1994) Lifespan of immunosuppressed NMRI-mice is increased by deprenyl. J Neural Transm [Suppl] 41: 231–236Google Scholar
  9. Gatti S, Bartfai T (1993) Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: comparison with interleukin-1 family and interleukin-6. Brain Res 624: 291–294PubMedCrossRefGoogle Scholar
  10. Gabellec MM, Griffais R, Fillion G, Haour F (1995) Expression of interleukin-1α, interleukin-1ß and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Mol Brain Res 31: 122–130PubMedCrossRefGoogle Scholar
  11. Gerlach M, Riederer P, Youdim MB (1995) Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochem Pharmacol 50: 1–16PubMedCrossRefGoogle Scholar
  12. Glavin GB, Dugani AM, Pinsky C (1986) L-deprenyl attenuates stress ulcer formation in rats. Neurosci Lett 70: 379–381PubMedCrossRefGoogle Scholar
  13. Gottschall PE, Komaki G, Arimura A (1991) Interleukin-1ß activation of the central nervous system. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 27–49Google Scholar
  14. Goujon E, Parnet P, Laye S, Combe C, Dantzer R (1996) Adrenalectomy enhances proinflammatory cytokines gene expression, in the spleen, pituitary and brain of mice in response to lipopolysaccharide. Mol Brain Res 36: 53–62PubMedCrossRefGoogle Scholar
  15. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611–7615PubMedCrossRefGoogle Scholar
  16. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 40: 445–452PubMedCrossRefGoogle Scholar
  17. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607–612PubMedCrossRefGoogle Scholar
  18. Imamura K, Suzumura A, Hayashi F, Marunouchi T (1993) Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87: 281–285PubMedCrossRefGoogle Scholar
  19. Imura H, Fukata J, Mori T (1991) Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol 35: 107–115CrossRefGoogle Scholar
  20. Inglot AD, Zielinska Jenczylik J, Piasecki E, Syper L, Mlochowski J (1990) Organoselenides as potential immunostimulants and inducers of interferon gamma and other cytokines in human peripheral blood leukocytes. Experientia 46: 308–311PubMedCrossRefGoogle Scholar
  21. Knoll J (1995) Rationale for (-)deprenyl (selegiline) medication in Parkinson’s disease and in prevention of age-related nigral changes. Biomed Pharmacother 49: 187–195PubMedCrossRefGoogle Scholar
  22. Kuhn W, Müller Th (1995) Neuroimmune mechanisms in Parkinson’s disease. J Neural Transm [Suppl] 46: 217–228Google Scholar
  23. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659–2667PubMedGoogle Scholar
  24. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21: 195–218PubMedCrossRefGoogle Scholar
  25. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994a) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147–150PubMedCrossRefGoogle Scholar
  26. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994b) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210PubMedCrossRefGoogle Scholar
  27. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T (1995) Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson’s disease. J Neural Transm [Park Dis Dement Sect] 9: 87–92CrossRefGoogle Scholar
  28. Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci AS (1990) Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 87: 782–785PubMedCrossRefGoogle Scholar
  29. Selmaj K, Raine CS (1988a) Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue. Ann NY Acad Sci 540: 568–570PubMedCrossRefGoogle Scholar
  30. Selmaj K, Raine CS (1988b) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339–346PubMedCrossRefGoogle Scholar
  31. Selmaj K, Bradbury K, Chapman J (1988a) Multiple sclerosis: effects of activated T-lymphocyte-derived products on organ cultures of nervous tissue. J Neuroimmunol 18: 255–268PubMedCrossRefGoogle Scholar
  32. Selmaj K, Nowak Z, Tchorzewski H (1988b) Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients. J Neurol Sci 85: 67–76PubMedCrossRefGoogle Scholar
  33. Selmaj K, Papierz W, Glabinski A, Kohno T (1995) Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56: 135–141PubMedCrossRefGoogle Scholar
  34. Stoll S, Hafner U, Pohl O, Müller WE (1994) Age-related memory decline and longevity under treatment with selegiline. Life Sci 55: 2155–2163PubMedCrossRefGoogle Scholar
  35. Strijbos PJ, Rothwell NJ (1995) Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J Neurosci 15: 3468–3474PubMedGoogle Scholar
  36. Tatton WG, Ansari K, Ju W, Salo PT, Yu PH (1995) Selegiline induces “trophic-like” rescue of dying neurons without MAO inhibition. Adv Exp Med Biol 363: 15–16PubMedCrossRefGoogle Scholar
  37. Thyagarajan S, Meites J, Quadri SK (1995) Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats. Endocrinology 136: 1103–1110PubMedCrossRefGoogle Scholar
  38. Wollmann EE, Kopmels B, Bakalian A, Delhaye-Bouchard N, Fradelizi D, Mariani J (1992) Cytokines and neuronal degeneration. In: Rothwell N, Dantzer R (eds) Interleukin in the brain. Pergamon Press, Oxford, pp 187–203Google Scholar
  39. Woodroofe MN (1995) Cytokine production in the central nervous system. Neurology 45: S6–S10PubMedCrossRefGoogle Scholar
  40. Yamaguchi M, Matsuzaki N, Hirota K, Miyake A, Tanizawa O (1990) Interleukin 6 possibly induced by interleukin 1 beta in the pituitary gland stimulates the release of gonadotropins and prolactin. Acta Endocrinol Copenh 122: 201–205PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • Th. Müller
    • 1
    • 1
  • W. Kuhn
    • 1
  • R. Krüger
    • 1
  • H. Przuntek
    • 1
  1. 1.Department of NeurologySt. Josef-Hospital, University of BochumBochumGermany

Personalised recommendations